Titre du document / Document title

Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis

Auteur(s) / Author(s)

TAKAGI Hitoshi ⁽¹⁾ ; KAKIZAKI Satoru ⁽¹⁾ ; SOHARA Naondo ⁽¹⁾ ; SATO Ken ⁽¹⁾ ; TSUKIOKA Gengo ⁽¹⁾ ; TAGO Youko ⁽¹⁾ ; KONAKA Kazuko ⁽¹⁾ ; KABEYA Kenshi ⁽¹⁾ ; KANEKO Mieko ⁽¹⁾ ; TAKAYAMA Hisashi ⁽¹⁾ ; HASHIMOTO Yoshiaki ⁽¹⁾ ; YAMADA Toshihiko ⁽¹⁾ ; TAKAHASHI Hitomi ⁽¹⁾ ; SHIMOJO Hiroshi ⁽¹⁾ ; NAGAMINE Takeaki ⁽¹⁾ ; MORI Masatomo ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ The First Department of Internal Medicine, Gunma University Faculty of Medicine, 3-39-15, Showa Machi Maebashi, 371-8511, JAPON

Résumé / Abstract

Patients with chronic hepatitis C virus (HCV) infection often develop liver cirrhosis and hepatocellular carcinoma (HCC). The purpose of this study was to test the chemopreventive effect of alpha-tocopherol on hepatocarcinogenesis in patients with liver cirrhosis and a history of HCV infection. Eighty-three patients with liver cirrhosis and with positive history of HCV infection were divided at random into two groups. Forty-four patients were treated with alpha-tocopherol (Vit E group) while the other 39 were followed as controls. The clinical background (gender, age, and laboratory data) was similar in the two groups. Serum levels of alpha-tocopherol, albumin, alanine aminotransferase (ALT), and total cholesterol and platelet count were measured serially over a period of five years. The mean serum concentration of alpha-tocopherol was low in both groups at entry and was significantly higher in the Vit E group than in the control group one month after treatment. Platelet count, serum albumin, ALT, and total cholesterol were not different between the two groups during the live-year period. Cumulative tumor-free survival and cumulative survival rate tended to be higher in the Vit E group than in controls, albeit statistically insignificant. The serum level of alpha-tocopherol was low in patients with liver cirdrosis and positive for HCV. Although the administration of alpha-tocopherol normalized the level one month later, it could neither improve liver function, suppress hepatocarcinogenesis, nor improve cumulative survival. survival. Patients treated with alpha-tocopherol tended to live longer without development of HCC but the difference was not statistically significant.

Revue / Journal Title

International journal for vitamin and nutrition research   ISSN 0300-9831   CODEN IJVNAP 

Source / Source

2003, vol. 73, n^o6, pp. 411-415 [5 page(s) (article)] (22 ref.)

Langue / Language

Anglais

Editeur / Publisher

Hogrefe & Huber, Bern, SUISSE  (1971) (Revue)

Mots-clés anglais / English Keywords

Malignant tumor ; Hepatic disease ; Digestive diseases ; Feeding ; Micronutrient ; Vitamin ; Human ; Clinical trial ; Cirrhosis ; Prevention ; Hepatocellular carcinoma ; Anticarcinogen ; Biological activity ; Supplemented diet ; α-Tocopherol ;

Mots-clés français / French Keywords

Tumeur maligne ; Foie pathologie ; Appareil digestif pathologie ; Alimentation ; Micronutriment ; Vitamine ; Homme ; Essai clinique ; Cirrhose ; Prévention ; Carcinome hépatocellulaire ; Anticarcinogène ; Activité biologique ; Régime alimentaire enrichi ; α-Tocophérol ;

Mots-clés espagnols / Spanish Keywords

Tumor maligno ; Hígado patología ; Aparato digestivo patología ; Alimentación ; Micronutriente ; Vitamina ; Hombre ; Ensayo clínico ; Cirrosis ; Prevención ; Carcinoma hepatocelular ; Anticarcinógeno ; Actividad biológica ; Régimen alimenticio enriquecido ; α-Tocoferol ;

Mots-clés d'auteur / Author Keywords

alpha-tocopherol ; HCV ; liver cirrhosis ; hepatocellular carcinoma ; chemoprevention ;

Localisation / Location

INIST-CNRS, Cote INIST : 844, 35400011906139.0020